Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment

Journal of Nervous and Mental Disease

Volumn 201, Issue 12, 2013, Pages 1085-1089

  Lecomte, Tania ^a   Mueser, Kim T ^b   Macewan, William ^c   Thornton, Allen E ^d   Buchanan, Tari ^c   Bouchard, Vanessa ^a   Goldner, Elliot ^e   Brink, Johann ^c   Lang, Donna ^c   Kang, Shimi ^c   Barr, Alasdair M ^c   Honer, William G ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b BOSTON UNIVERSITY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Department of Psychology ^*  (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

depression; dual disorder; methamphetamine; Psychosis

Indexed keywords

ADULT; ANTISOCIAL BEHAVIOR; ANTISOCIAL PERSONALITY DISORDER; ARTICLE; DEPRESSION; FAMILY HISTORY; FEMALE; HUMAN; INJURY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; METHAMPHETAMINE DEPENDENCE; POSITIVE SYNDROME; PSYCHIATRIC TREATMENT; PSYCHOSIS;

ADULT; AGE FACTORS; AMPHETAMINE-RELATED DISORDERS; ANTISOCIAL PERSONALITY DISORDER; DEPRESSION; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; LONGITUDINAL STUDIES; MALE; METHAMPHETAMINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; TIME FACTORS;

EID: 84889776084     PISSN: 00223018     EISSN: 1539736X     Source Type: Journal    
DOI: 10.1097/NMD.0000000000000059     Document Type: Article

References (45)

1. Addington J, Addington D (1998) Effect of substance misuse in early psychosis. Br J Psychiatry Suppl. 172:134-136
2. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DM, Honer WG, Lecomte T (2006) The need for speed: An update on methamphetamine addiction. J Psychiatry Neurosci. 31:301-313
3. Beck AT, Steer RA, Ball R, Ranieri W (1996) Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess. 67:588-597
4. Bendall S, Jackson HJ, Hulbert CA, McGorry PD (2008) Childhood trauma and psychotic disorders: A systematic, critical review of the evidence. Schizophr Bull. 34:568-569
5. Bezard E, Dovero S, Belin D, Duconger S, Jackson-Lewis V, Przedborski S, Jaber M (2003) Enriched environment confers resistance to 1-methyl-4-phenyl-1,2, 3,6-Tetrahydropyridine and cocaine: Involvement of dopamine transporter and trophic factors. J Neurosci. 23:1099-1107
6. Bretch M-L, O'Brien A, von Mayrhauser C, Anglin MD (2004) Methamphetamine use behaviors and gender differences. Addict Behav. 29:89-106
7. Buhler B, Hambrecht M, LofflerW, An der HeidenW, Hafner H (2002) Precipitation and determination of the onset and course of schizophrenia by substance abuseVA retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res. 54:243-251
8. Chen C-K, Lin S-K, Sham PS, Ball SD, Loh E-W, Hsiao C-C, Murray RM (2003) Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 33:1407-1414
9. Chen CK, Lin SK, Sham PK, Ball D, Loh EW, Murray RM (2005) Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet. 136B:87-91
10. Conway KP, Compton W, Stinson FS, Grant BF (2006) Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 67:247-257
11. Cretzmeyer M, Vaughan Sarrazin M, Huber DL, Block RI, Hall JA (2003) Treatment of methamphetamine abuse: Research findings and clinical directions. J Subst Abuse Treat. 24:267-277
12. Cutajar MC, Mullen PE, Ogloff JR, Thomas SD, Wells DL, Spataro J (2010) Psychopathology in a large cohort of sexually abused children followed up to 43 years. Child Abuse Negl. 34:813-822
13. Dore G, Sweeting M (2006) Drug-induced psychosis associated with crystalline methamphetamine. Australas Psychiatry. 14:86-89
14. Drake R, Mercer-McFadden C, Mueser KT, McHugo G, Bond GR (1998) Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull. 24:589-607
15. Drake R, Mueser KT, Brunette MF, McHugo G (2004) A review of treatments for patients with severe mental illness and co-occuring substance use disorders. Psychiatr Rehabil J. 27:360-374
16. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV axis I and II disordersVPatient edition. New York: Biometrics Research Department
17. Fowler IL, Carr VJ, Carter NT, Lewin TJ (1998) Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull. 24:443-455
18. Gaudiano BA, Dalrymple KL, Zimmerman M (2009) Prevalence and clinical characteristics of psychotic versus nonpsychotic major depression in a general psychiatric outpatient clinic. Depress Anxiety. 26:54-64
19. Grelotti DJ, Kanayama G, Pope HG Jr (2010) Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: Presentation of a case and review of the literature. Am J Psychiatry. 167:17-23. doi:10.1176/appi.ajp.2009.08111695
20. Hafner H, an der Heiden W, Maurer K (2008) Evidence for separate diseases: Stages of one disease or different combinations of symptom dimensions Eur Arch Psychiatry Clin Neurosci. 258(suppl 2):85-96
21. Halkitis PN (2009) Methamphetamine addiction. Washington, DC: American Psychological Association
22. Hambrecht M, Hafner H (1996) Substance abuse and the onset of schizophrenia. Biol Psychiatry. 40:1155-1163
23. Jones BL, Nagin DS, Roeder K (2001) A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 29:374-393
24. Lecomte T, Mueser KT, MacEwan WG, Laferrière-Simard M-C, Thornton AE, Buchanan T, Honer WG (2010) Profiles of individuals seeking psychiatric help for psychotic symptoms linked to methamphetamine abuseVBaseline results from the MAPS (Methamphetamine and Psychosis Study). Ment Health Subst Use Dual Diagn. 3:168-181
25. Lichlyter B, Purdon S, Tibbo P (2011) Predictors of psychosis severity in individuals with primary stimulant addictions. Addict Behav. 36:137-139
26. McKetin R, McLaren J, Lubman DI, Hides L (2006) The prevalence of psychotic symptoms among methamphetamine users. Addiction. 101:1473-1478
27. Mikami T, Naruse N, Fukura Y, Ohkubo H, Ohkubo T, Matsuura M, Kojima T (2003) Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements. Psychiatry Clin Neurosci. 57:433-440. doi:10.1046/j.1440-1819.2003.01143.x.
28. Mueser KT, Frisman LB, Drake R, Covell NH, Essock SM (2006) Conduct disorder and antisocial personality disorder in persons with severe psychiatric and substance use disorders. Schizophr Bull. 32:626-636
29. Mueser KT, Noordsy DL, Drake RE, Fox LB (2003) Integrated treatment for dual disordersVA guide to effective practice. New York: The Guilford Press
30. Mueser KT, Salyers MP, Rosenberg SD, Ford JD, Fox L, Cardy P (2001) A psychometric evaluation of trauma and PTSD assessments in persons with severe mental illness. Psychol Assess. 13:110-117
31. Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS, Kee K, Yadalam KG (1990a) Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr Bull. 16:31-56
32. Mueser KT, Yarnold PR, Levinson DF, Singh H, Bellack AS, Kee K, Yadalam KG (1990b) Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr Bull. 16:31-56
33. PCR (2002) Lower mainland youth drug survey. Surrey, Canada: Pacific Community Resources
34. Rawson R, Gonzales R, Brethen P (2002) Treatment of methamphetamine use disorders: An update. J Subst Abuse Treat. 23:145-150
35. Reiber C, Galloway GP, Cohen J, Hsu JC, Lord RH (2000) A descriptive analysis of participant characteristics and patterns of substance use in the CSAT methamphetamine treatment project: The first six months. J Psychoactive Drugs. 32:183-191
36. Salo R, Flower K, Kielstein A, Leamon M, Nordahl TE, Galloway GP (2011) Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 186:356-361
37. Schnurr PP, Vielhauer MJ, Weathers F, Findler M (1999) The Brief Trauma Questionnaire. White River Junction, VT: National Center for PTSD
38. Sobell MB, Maisto SA, Sobell LC, Copper AM, Sanders B (1980) Developing a prototype for evaluating alcohol treatment effectiveness. In Sobell LC, Sobell MB, Ward E (Eds), Evaluating alcohol and drug abuse treatment effectiveness (pp 129-150). New York: Pergamon Press
39. Srisurapanont M, Arunpongpaisal S, Wada K, Marsden J, Ali R, Kongsakon R (2011) Comparisons of methamphetamine psychotic and schizophrenic symptoms: A differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry. 35:959-964
40. Tsuang MT (1994) Genetics, epidemiology, and the search for causes of schizophrenia. Am J Psychiatry. 151:3-6
41. Ventura J, Green M, Shaner A, Liberman RP (1993) Training and quality assurance with the Brief Psychiatric Rating Scale. Int J Methods Psychiatr Res. 3:221-244
42. World Health Organization (1997) World Health Organization. Amphetaminelike stimulants: A report from the WHO meeting an amphetamines, MDMA and other psychostimulants. Geneva, Switzerland: Substance Abuse Department, WHO
43. Yui K, Ikemoto S, Goto K, Nishijima K, Yoshino T, Ishiguro T (2002a) Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: Susceptibility to psychotic states and implications for relapse of schizophrenia. Pharmacopsychiatry. 35:62-71
44. Yui K, Ikemoto S, Ishiguro T, Goto K (2002b) Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. Ann N Y Acad Sci. 965:292-304
45. Zanis DA, McLellan A, Thomas CS (1997) Is the Addiction Severity Index a reliable and valid assessment instrument among clients with severe and persistent mental illness and substance abuse disorders Community Ment Health J. 33:213-227